Jon Filderman

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington.

UBS AG's (NYSE: UBS) New York City-based wealth management arm is known as UBS Private Banking (US). The firm provides a range of customized wealth management products and services for private clients.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA.

Organovo, Inc. develops and supplies pharmaceutical products. It focuses on delivering human tissue printing technology and creating tissue on demand for research and surgical applications. The firm helps physicians and researchers fulfill the promise of regenerative medicine by overcoming problems in cardiovascular medicine, medical research and transplant medicine. The company was founded by Eric Michael David, Andras Forgacs, Gabor Forgacs and Keith Murphy in 2007 and is headquartered in San Diego, CA.

Arcturus Therapeutics, Inc. engages in the development of technology and therapeutics for rare diseases. It specializes in the application of application of ribonucleic acid technologies for the treatment of disease. The company was founded by Joseph E. Payne and Padmanabh Chivukula in 2013 and is headquartered in San Diego, CA.

Part of DURECT Corp., IntraEAR, Inc. is a company that develops drug delivery devices for inner-ear maladies. The company is based in Greenwood Village, CO. IntraEAR was acquired by DURECT Corp. on October 06, 1999. The company was founded by Dan K. Arenberg, Michael H. Arenberg.

Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA.

BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA.

H.I.G. BioHealth Partners LLC (H.I.G. BioHealth Partners) is a private equity and venture capital subsidiary of H.I.G. Ventures LLC founded in 1993. The firm is headquartered in Miami, Florida with additional offices around the globe.

FLAP LLC provides licensing and royalty services for medicines. The company was founded in 2011 and is headquartered in San Diego, CA.

Panmira Pharmaceuticals LLC provides drug development programs. It develops pharmaceutical products for inflammatory diseases. The company was founded in September 2011 and is headquartered in San Diego, CA.

Aravive Biologics, Inc. develops novel targeted therapeutics in oncology. The company was founded by Amato Giaccia and Albert Koong and is headquartered in Houston, TX.

Hawkeye Therapeutics, Inc. licenses and develops assets from pharmaceutical companies. The company is headquartered in San Diego, CA.

Cirius Therapeutics, Inc. operates as a biotechnology company. It offers metabolic treatment for nonalcoholic steatohepatitis. The company was founded by Jerry R. Colca and Brian Finck and was founded in March 2017, and is headquartered in San Diego, CA.

Attenua, Inc. engages in the provision of biopharmaceutical services. The company was founded by Jing Liang and is headquartered in San Mateo, CA.

Mavupharma, Inc. engages development of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. The company was founded by W. Michael Gallatin, Brian K. Farmer, and Robert F. Baltera, Jr. and is headquartered in Kirkland, WA.

Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA.

Inipharm, Inc. provides health care services. The company was founded by Brian Farmer and Mike Gallatin in 2018 and is headquartered in Bellevue, WA.

Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation.

Trestle Biotherapeutics, Inc. is a pre-clinical stage company that develops bioengineered therapies for patients with end-stage renal disease. Trestle Biotherapeutics is based in Encinitas, CA. The company's goal is to create bioengineered stem cell-derived tissues that can replace damaged organs, delay the need for transplantation, and get patients off dialysis. The company was founded by Ben Shepherd and Robert F. Baltera, and Ben Shepherd has been the CEO since incorporation.